RHYTHM PHARMACEUTICALS

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

23 янв 2023 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

05 янв 2023 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 дек 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present at BofA Securities 2022 Virtual Biotech SMID Cap Conference

01 дек 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

21 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology

08 ноя 2022 06:05:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update

08 ноя 2022 06:00:04 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

07 ноя 2022 15:01:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®

03 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023

02 ноя 2022 06:30:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA

01 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022

25 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022

12 окт 2022 07:00:02 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development

06 окт 2022 15:02:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

06 окт 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)

23 сен 2022 07:00:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering

19 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

19 сен 2022 07:00:01 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering

14 сен 2022 21:20:00 Источник Nasdaq GlobeNewswire

Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering

14 сен 2022 15:01:00 Источник Nasdaq GlobeNewswire